secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2025-08-27T23:59:59+00:00
Accession:  0001140361-25-032847
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts Grace Therapeutics' NDA for GTx-104; PDUFA date set for April 23, 2026
--------------------------------------------------------------------------------

- FDA accepted NDA for GTx-104 (injectable nimodipine) for aSAH treatment; PDUFA target April 23, 2026.
- Acceptance triggers up to $7.6M in warrants exercisable at $3.003/share, expiring 60 days post-acceptance or Sept 25, 2028.
- Phase 3 STRIVE-ON trial met primary endpoint: 19% reduction in clinically significant hypotension vs oral nimodipine (28% vs 35%).
- GTx-104 showed 54% of patients had ≥95% relative dose intensity vs 8% for oral; 29% more favorable functional outcomes at 90 days.
- Orphan Drug Designation provides 7-year US marketing exclusivity if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125032847/0001140361-25-032847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125032847/ef20054617_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-032847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer